Form 4: Oramed Pharmaceuticals Insider Trades

Joshua Hexter, COO & CBO of Oramed Pharmaceuticals, reported transactions involving the sale of common stock and the exercise of stock options.

Summary

• Joshua Hexter, Chief Operating Officer and Chief Business Officer of Oramed Pharmaceuticals Inc., filed a Form 4 detailing transactions on July 1st and July 2nd, 2026.
• On July 1st, 2026, Hexter sold 137,000 shares of common stock at a weighted average price of $4.463, with individual sales ranging from $4.255 to $4.7652.
• These sales were conducted under a Rule 10b5-1 trading plan adopted on March 30, 2026.
• On July 2nd, 2026, Hexter acquired 50,000 shares through the exercise of stock options at a price of $3.69 per share.
• Following these transactions, Hexter beneficially owns 1,073,384 shares of common stock directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the significant sale of shares by a key executive, despite being executed under a pre-planned trading strategy.

Positives

• The sale of shares was executed under a pre-established Rule 10b5-1 trading plan, indicating a planned and orderly divestment rather than a reactive decision.
• Hexter exercised stock options, acquiring shares at a price ($3.69) lower than the average sale price ($4.463) on the following day, potentially indicating a profitable transaction for the executive.

Negatives

• A significant number of shares (137,000) were sold by a key executive, which could be interpreted negatively by the market.
• The sale of shares under a 10b5-1 plan, while compliant, still represents a reduction in insider ownership.

Risks

• The sale of a substantial number of shares by a senior executive could signal a lack of confidence in the company's near-term prospects, potentially impacting investor sentiment.
• While the transactions were made under a 10b5-1 plan, the sheer volume of shares sold might raise questions about the executive's personal financial strategy or outlook on the company's stock performance.

Future Outlook

No specific forward-looking statements or guidance were provided in this Form 4 filing, which primarily reports past transactions.

Management Comments

• The sale of shares was conducted pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
• The stock options vested and became exercisable in 16 equal installments of 6,250 on the first day of every three-month period beginning November 1, 2019.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common event in the pharmaceutical sector. However, the volume of shares sold by a COO & CBO warrants attention, especially in a company focused on drug development where significant capital events and clinical trial results can heavily influence stock price.

Stakeholder Impact

• Shareholders: May perceive the sale of shares by a key executive as a negative signal, potentially impacting stock price. However, the use of a 10b5-1 plan mitigates concerns about insider trading.
• Employees: May be concerned about executive confidence in the company's future, though the transaction is primarily financial.
• Creditors: Unlikely to be directly impacted by this insider transaction.

Next Steps

• Monitor future SEC filings for any further transactions by Joshua Hexter or other Oramed Pharmaceuticals insiders.
• Observe the market reaction to these reported transactions.

Key Dates

Recommendation

The filing reports routine insider transactions under a 10b5-1 plan. While the sale of a significant number of shares by a COO & CBO is noted, the structured nature of the sale suggests it's for personal financial planning rather than a reflection of negative company outlook. The exercise of options at a lower price than the sale price is a neutral to slightly positive indicator for the executive's personal financial gain. Without further operational or financial data, a 'hold' recommendation is prudent, advising investors to monitor future developments.

Keywords

Form 4, Insider Trading, Oramed Pharmaceuticals, ORMP, Joshua Hexter, Stock Options, Rule 10b5-1, Beneficial Ownership, SEC Filing